What's more, a lot of well proven adverse prognostic markers, like U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, shed their adverse effect in people treated with VO. The one aspect that remained predictive of the shorter progression-cost-free survival Within this cohort of clients was TP53 aberrations.112 Ultimately, the choice BTK inhibitor ac